12:00 AM
Mar 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

RX-3117: Phase I started

Rexahn began a European Phase I trial to evaluate oral RX-3117 in cancer patients. Teva has exclusive, worldwide rights to develop and commercialize...

Read the full 95 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >